TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: Recent advances in the targeted treatment of MTNKL and inclusion of indolent-behaving cutaneous T-cell lymphomas (CTCL) such as mycosis fungoides or primary cutaneous CD30+ T-cell lymphoproliferative disorders likely improve these statistics, though treatment of relapsed and refractory disease remains a major unmet need.